(Q48606526)

13 February 2018

title

Safety of vaccine adjuvants: focus on autoimmunity (English)

1 reference

13 February 2018

author name string

Jan Willem van der Laan

1

1 reference

13 February 2018

Sarah Gould

2

1 reference

13 February 2018

Jennifer Y Tanir

3

1 reference

13 February 2018

ILSI HESI Vaccines and Adjuvants Safety Project Committee

4

1 reference

13 February 2018

language of work or name

English

0 references

publication date

7 February 2015

1 reference

13 February 2018

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

13 February 2018

volume

33

1 reference

13 February 2018

issue

13

1 reference

13 February 2018

page(s)

1507-1514

1 reference

13 February 2018

European union regulatory developments for new vaccine adjuvants and delivery systems

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Current adjuvants and new perspectives in vaccine formulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Paths to understanding the genetic basis of autoimmune disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Toll-like receptors in systemic autoimmune disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Trends in vaccine adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

The mechanism of action of MF59 - an innately attractive adjuvant formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Defining criteria for autoimmune diseases (Witebsky's postulates revisited)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Animal models in autoimmune diseases: lessons learned from mouse models for Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Acanthamoeba on Sabouraud's agar from a patient with keratitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Structure-activity relations of water-in-oil vaccine formulations and induced antigen-specific antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Adjuvant oil induces waves of arthritogenic lymph node cells prior to arthritis onset

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Distinctive patterns of autoimmune response induced by different types of mineral oil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Innate immunity and intestinal microbiota in the development of Type 1 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Toll-like receptor 7 stimulation promotes autoimmune diabetes in the NOD mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Validation of new biomarkers in systemic autoimmune diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Regulatory T cells that recognize a ubiquitous stress-inducible self-antigen are long-lived suppressors of autoimmune arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Insights into the role of Toll-like receptors in modulation of T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Induction of autoimmunity by pristane and other naturally occurring hydrocarbons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Adjuvants and autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Immunology. Key narcolepsy-influenza vaccine findings retracted

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.073

10.1016/J.VACCINE.2015.01.073

7 January 2021

Identifiers

DOI

1 reference

13 February 2018

1 reference

13 February 2018